As regenerative medicine matures as a field, more promising technologies are being translated from the benchtop to the clinic. However, many of these strategies are designed with otherwise healthy hosts in mind and validated in animal models without other co-morbidities. In reality, many of the patient populations benefiting from drug delivery and tissue engineering-based devices to enhance wound healing also have significant underlying immunodeficiency. Specifically, patients suffering from diabetes, malignancy, human immunodeficiency virus, post-organ transplantation, and other compromised states have significant pleotropic immune defects that affect wound healing. In this work, we review the role of different immune cells in the regenerative process, highlight the effect of several common immunocompromised states on wound healing, and discuss different drug delivery strategies for overcoming immunodeficiencies.

随着再生医学作为一个领域的成熟，更多有前景的技术正在从实验室转移到临床。然而，许多这些策略都是在考虑其他健康宿主的情况下设计的，并在没有其他合并症的动物模型中得到验证。事实上，许多受益于药物输送和基于组织工程的设备来促进伤口愈合的患者群体也患有严重的潜在免疫缺陷。具体来说，患有糖尿病、恶性肿瘤、人类免疫缺陷病毒、器官移植后和其他受损状态的患者具有显着的多效性免疫缺陷，影响伤口愈合。在这项工作中，我们回顾了不同免疫细胞在再生过程中的作用，强调了几种常见的免疫功能低下状态对伤口愈合的影响，并讨论了克服免疫缺陷的不同药物输送策略。